Business Context and Reporting Period
Company: NeoStem, Inc. (Note: Metadata referenced "Lisata Therapeutics," but the filing text identifies the registrant as NeoStem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: NeoStem operates a commercial autologous adult stem cell bank and is pioneering the collection, processing, and storage of stem cells for future medical treatment. The company is expanding into research and development (R&D) via VSEL (very small embryonic-like) stem cell technology and is aggressively pursuing expansion into the People's Republic of China (PRC) through a Wholly Foreign Owned Enterprise (WFOE) and Variable Interest Entities (VIEs). The company is also pursuing a proposed merger with China Biopharmaceuticals Holdings, Inc. (CBH).
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $76,738 | $24,221 |
| Gross Profit | $37,438 | $20,313 |
| Operating Loss | $(6,556,266) | $(4,883,405) |
| Net Loss | $(6,558,608) | $(4,888,962) |
| Net Loss Attributable to Common Shareholders | $(6,810,335) | $(4,888,962) |
| Cash and Cash Equivalents (End of Period) | $10,449,531 | $529,095 |
| Working Capital | $10,011,016 | N/A |
| Total Liabilities | $943,970 | $961,140 |
| Stockholders' Equity | $3,794,806 | $863,176 |
Note: The company reported a significant increase in cash balances due to private placement financing activities during the period.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 217% to $76,738 for the six months ended June 30, 2009, compared to $24,221 in the prior year period. This was driven by milestone income from a licensing agreement with Enhance BioMedical, stem cell collection/storage fees, and network fees.
- Operating Expenses: Selling, general, administrative, and research expenses increased 34% to $6,593,704. The increase was primarily due to:
- China expansion activities (approx. $1.14 million increase), including lab rent, legal fees, and recruiting.
- Merger-related costs with CBH (approx. $677,000 increase).
- Increased VSEL research expenses in the U.S. (approx. $406,000 increase).
- Liquidity Position: Cash and cash equivalents surged from $430,786 at year-end 2008 to $10,449,531 at June 30, 2009. This was driven by net proceeds of approximately $15.7 million from two private placements of Series D Convertible Redeemable Preferred Stock and warrants in April and June 2009.
- Debt: The company repaid $1.15 million in promissory notes to a related party (RimAsia) in April 2009 using proceeds from the private placement. Remaining notes payable at June 30, 2009, were $38,798 related to insurance policies.
Guidance, Outlook, Risks, and Unusual Items
- Merger with CBH: The company is pursuing a merger with China Biopharmaceuticals Holdings, Inc. (CBH) to acquire a 51% interest in Suzhou Erye Pharmaceuticals. The merger agreement was amended in July 2009, extending the outside date for completion to October 31, 2009. Closing is anticipated in the fourth quarter of 2009, subject to shareholder approval.
- China Expansion: NeoStem has established a WFOE and VIEs in China to navigate regulatory prohibitions on foreign investment in stem cell research. The company expects to incur substantial expenses for these initiatives and anticipates needing additional funding.
- Series D Preferred Stock: The company issued Series D Preferred Stock with a 10% annual dividend. If shareholder approval for conversion to common stock is not achieved by October 31, 2009, the company must redeem the shares at $12.50 per share plus accrued dividends (total redemption obligation approx. $16.2 million).
- Liquidity Risk: Despite the recent cash infusion, management states that the company will need to raise substantial additional funds to support its platform business, China expansion, and R&D. There is no assurance that additional funding will be available on acceptable terms.
- Unusual Items: The company terminated a Share Exchange Agreement regarding Shandong New Medicine Research Institute in July 2009, opting instead to build its own stem cell business in China. Significant stock-based compensation was issued to consultants and employees during the period.
Investor Verification Checklist
- Merger Approval: Verify the status of shareholder votes required for the CBH merger and the conversion of Series D Preferred Stock, with a critical deadline of October 31, 2009.
- Redemption Obligation: Assess the company's ability to meet the potential $16.2 million redemption obligation for Series D Preferred Stock if the merger/conversion fails.
- China Regulatory Structure: Review the risks associated with the Variable Interest Entity (VIE) structure used to operate in China, given the "prohibited" status of foreign investment in stem cell research under PRC law.
- Burn Rate vs. Cash: Monitor the rate of cash consumption given the high operating losses (~$6.8M for six months) against the current cash balance of ~$10.4M.
- Revenue Sustainability: Evaluate the sustainability of revenue growth, which remains minimal ($76k for six months) relative to the scale of operations and expenses.